GlaxoSmithKline Pharmaceuticals declared a final dividend of ₹57 per equity share for FY26, marking one of the company's highest shareholder payouts on record. According to the latest regulatory filing, this payout represents the company's third-highest dividend to date, following ₹62.5 per share in 2015 and ₹60 per share in 2022. The board recommended the dividend subject to shareholder approval at the 101st Annual General Meeting scheduled for June 30, 2026. As per the company's regulatory disclosure, Friday, May 29, 2026 has been fixed as the record date for determining shareholder eligibility for the dividend.
The MNC drugmaker delivered robust financial results for Q4 FY26, demonstrating consistent growth across key metrics. According to the latest regulatory filing, consolidated net profit rose 5.7% to ₹277.86 crore compared to ₹262.87 crore in the corresponding quarter last year, while revenue from operations grew 2.1% to ₹995.3 crore compared to ₹974.37 crore in Q4 FY25. The company achieved FY26 consolidated net profit of ₹1,035.98 crore, representing a 10.4% increase from ₹927.58 crore in FY25, with revenue from operations reaching ₹3,821.67 crore compared to ₹3,749.21 crore in the previous fiscal year. EBITDA margin expanded slightly to 35.3% from 34.2% in the year-ago period, supported by better operational efficiencies and improved profitability metrics. The company's FY26 revenue increased 2% year-over-year with EBITDA growing 11%, driven by an innovative portfolio especially in oncology and respiratory segments, while key brands maintained market leadership positions.
GSK Pharma has established May 29, 2026 as the record date for determining shareholder eligibility for the dividend. According to the company's regulatory disclosure, if approved at the AGM, the dividend will be paid on or after July 1, 2026, subject to applicable tax deductions. Following the earnings announcement, shares of GlaxoSmithKline Pharmaceuticals were trading 1.27% lower at ₹2,417 on BSE on Wednesday. The company operates as the Indian arm of British pharmaceutical major GlaxoSmithKline, focusing on prescription medicines and vaccines in India.
